Trial Information
Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Inclusion Criteria:
- Patients with neurofibromatosis type 1, between 6 and 50 years old
Exclusion Criteria:
- Patients who are not allowed to be scanned on MRI (contra-indications: pacemaker ed.)
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Estimation of total tumor load and diagnosis of high-risk neurofibromas
Outcome Description:
Estimation of the total tumor load of neurofibromas with whole body MRI (head to knee). Diagnosis of high risk neurofibroma in the chest, abdomen, pelvis, and extremities with T2-weighted sequence and diffusion weighted sequence.
Outcome Time Frame:
1 month
Safety Issue:
No
Principal Investigator
Steven Pans, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Universitaire Ziekenhuizen Leuven
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
NEFIMAR
NCT ID:
NCT01777451
Start Date:
December 2010
Completion Date:
January 2014
Related Keywords:
- Whole Body Imaging
- Magnetic Resonance Imaging
- Neurofibromatosis 1
- Diffusion Magnetic Resonance Imaging
- Peripheral Nerve Sheath Tumors, Malignant
- Whole Body Imaging
- Magnetic Resonance Imaging
- Neurofibromatosis 1
- Diffusion Magnetic Resonance Imaging
- Peripheral Nerve Sheath Tumors, Malignant
- Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Osteitis Fibrosa Cystica
- Nerve Sheath Neoplasms
- Neurofibrosarcoma
- Neurilemmoma